Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 50

1.

First-in-Class, First-in-Human Study Evaluating LV305, a Dendritic-Cell Tropic Lentiviral Vector, in Sarcoma and Other Solid Tumors Expressing NY-ESO-1.

Somaiah N, Block MS, Kim JW, Shapiro GI, Do KT, Hwu P, Eder JP, Jones RL, Lu H, Ter Meulen JH, Bohac C, Chen M, Hsu FJ, Gnjatic S, Pollack SM.

Clin Cancer Res. 2019 Jun 21. doi: 10.1158/1078-0432.CCR-19-1025. [Epub ahead of print]

PMID:
31227504
2.

Systemic Interferon-γ Increases MHC Class I Expression and T-cell Infiltration in Cold Tumors: Results of a Phase 0 Clinical Trial.

Zhang S, Kohli K, Black RG, Yao L, Spadinger SM, He Q, Pillarisetty VG, Cranmer LD, Van Tine BA, Yee C, Pierce RH, Riddell SR, Jones RL, Pollack SM.

Cancer Immunol Res. 2019 Aug;7(8):1237-1243. doi: 10.1158/2326-6066.CIR-18-0940. Epub 2019 Jun 6.

PMID:
31171504
3.

MRI Radiomic Features Are Independently Associated With Overall Survival in Soft Tissue Sarcoma.

Spraker MB, Wootton LS, Hippe DS, Ball KC, Peeken JC, Macomber MW, Chapman TR, Hoff MN, Kim EY, Pollack SM, Combs SE, Nyflot MJ.

Adv Radiat Oncol. 2019 Feb 23;4(2):413-421. doi: 10.1016/j.adro.2019.02.003. eCollection 2019 Apr-Jun.

4.

Mobilization of CD8+ T Cells via CXCR4 Blockade Facilitates PD-1 Checkpoint Therapy in Human Pancreatic Cancer.

Seo YD, Jiang X, Sullivan KM, Jalikis FG, Smythe KS, Abbasi A, Vignali M, Park JO, Daniel SK, Pollack SM, Kim TS, Yeung R, Crispe IN, Pierce RH, Robins H, Pillarisetty VG.

Clin Cancer Res. 2019 Jul 1;25(13):3934-3945. doi: 10.1158/1078-0432.CCR-19-0081. Epub 2019 Apr 2.

PMID:
30940657
5.

Systemic Anti-Cancer Therapy in Synovial Sarcoma: A Systematic Review.

Riedel RF, Jones RL, Italiano A, Bohac C, Thompson JC, Mueller K, Khan Z, Pollack SM, Van Tine BA.

Cancers (Basel). 2018 Nov 1;10(11). pii: E417. doi: 10.3390/cancers10110417. Review.

6.

Response to PD1 inhibition in conventional chondrosarcoma.

Wagner MJ, Ricciotti RW, Mantilla J, Loggers ET, Pollack SM, Cranmer LD.

J Immunother Cancer. 2018 Sep 25;6(1):94. doi: 10.1186/s40425-018-0413-z.

7.

Propranolol for the treatment of vascular sarcomas.

Wagner MJ, Cranmer LD, Loggers ET, Pollack SM.

J Exp Pharmacol. 2018 Sep 6;10:51-58. doi: 10.2147/JEP.S146211. eCollection 2018. Review.

8.

More Than 50 Subtypes of Soft Tissue Sarcoma: Paving the Path for Histology-Driven Treatments.

Katz D, Palmerini E, Pollack SM.

Am Soc Clin Oncol Educ Book. 2018 May 23;38:925-938. doi: 10.1200/EDBK_205423. Review.

PMID:
30231352
9.

Limited activity of metronomic cyclophosphamide and pembrolizumab for soft tissue sarcomas.

Lien IC, Pollack SM.

Transl Gastroenterol Hepatol. 2018 Jan 15;3:4. doi: 10.21037/tgh.2017.12.09. eCollection 2018. No abstract available.

10.

Advances in the treatment of soft tissue sarcoma: focus on eribulin.

Koliou P, Karavasilis V, Theochari M, Pollack SM, Jones RL, Thway K.

Cancer Manag Res. 2018 Feb 1;10:207-216. doi: 10.2147/CMAR.S143019. eCollection 2018. Review.

11.

The potential of the CMB305 vaccine regimen to target NY-ESO-1 and improve outcomes for synovial sarcoma and myxoid/round cell liposarcoma patients.

Pollack SM.

Expert Rev Vaccines. 2018 Feb;17(2):107-114. doi: 10.1080/14760584.2018.1419068. Epub 2017 Dec 27. Review.

12.

Emerging Targeted and Immune-Based Therapies in Sarcoma.

Pollack SM, Ingham M, Spraker MB, Schwartz GK.

J Clin Oncol. 2018 Jan 10;36(2):125-135. doi: 10.1200/JCO.2017.75.1610. Epub 2017 Dec 8. Review.

PMID:
29220291
13.

Safety and Efficacy Outcomes of Embolization in Hepatic Sarcomas.

Pierce DB, Johnson GE, Monroe E, Loggers ET, Jones RL, Pollack SM, Padia SA.

AJR Am J Roentgenol. 2018 Jan;210(1):175-182. doi: 10.2214/AJR.16.17573. Epub 2017 Nov 1.

PMID:
29090997
14.

First-in-Human Treatment With a Dendritic Cell-targeting Lentiviral Vector-expressing NY-ESO-1, LV305, Induces Deep, Durable Response in Refractory Metastatic Synovial Sarcoma Patient.

Pollack SM, Lu H, Gnjatic S, Somaiah N, O'Malley RB, Jones RL, Hsu FJ, Ter Meulen J.

J Immunother. 2017 Oct;40(8):302-306. doi: 10.1097/CJI.0000000000000183.

15.

Clinical benefit of antiangiogenic therapy in advanced and metastatic chondrosarcoma.

Jones RL, Katz D, Loggers ET, Davidson D, Rodler ET, Pollack SM.

Med Oncol. 2017 Aug 29;34(10):167. doi: 10.1007/s12032-017-1030-2.

16.

T-cell infiltration and clonality correlate with programmed cell death protein 1 and programmed death-ligand 1 expression in patients with soft tissue sarcomas.

Pollack SM, He Q, Yearley JH, Emerson R, Vignali M, Zhang Y, Redman MW, Baker KK, Cooper S, Donahue B, Loggers ET, Cranmer LD, Spraker MB, Seo YD, Pillarisetty VG, Ricciotti RW, Hoch BL, McClanahan TK, Murphy E, Blumenschein WM, Townson SM, Benzeno S, Riddell SR, Jones RL.

Cancer. 2017 Sep 1;123(17):3291-3304. doi: 10.1002/cncr.30726. Epub 2017 May 2.

17.

Phase III Soft Tissue Sarcoma Trials: Success or Failure?

Lee AT, Pollack SM, Huang P, Jones RL.

Curr Treat Options Oncol. 2017 Mar;18(3):19. doi: 10.1007/s11864-017-0457-1. Review.

18.

The Imaging and Pathological Features of Metastatic Leiomyosarcoma in the Gallbladder.

Guo Y, Chen E, Davidson DJ, Pillarisetty VG, Jones RL, Pollack SM.

Rare Tumors. 2016 Dec 23;8(4):6618. doi: 10.4081/rt.2016.6618. eCollection 2016 Nov 17.

19.

Treatment of refractory gastrointestinal stromal tumor using pazopanib.

Lien IC, Pollack SM.

Transl Gastroenterol Hepatol. 2016 Nov 29;1:86. doi: 10.21037/tgh.2016.11.01. eCollection 2016. No abstract available.

20.

Novel therapeutic approaches in chondrosarcoma.

Polychronidou G, Karavasilis V, Pollack SM, Huang PH, Lee A, Jones RL.

Future Oncol. 2017 Mar;13(7):637-648. doi: 10.2217/fon-2016-0226. Epub 2017 Jan 30. Review.

Supplemental Content

Loading ...
Support Center